Essex Bio-Technology Limited

SEHK:1061 Stock Report

Market Cap: HK$1.5b

Essex Bio-Technology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Essex Bio-Technology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth41.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06
Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Mar 21
Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Dec 07
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Aug 25
Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Jun 22
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30
Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31
Is Essex Bio-Technology (HKG:1061) A Risky Investment?

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13
If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04
Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23
Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Essex Bio-Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:1061 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20241,619263211316N/A
3/31/20241,663269211328N/A
12/31/20231,707275211339N/A
9/30/20231,634266169323N/A
6/30/20231,561256127307N/A
3/31/20231,439241113345N/A
12/31/20221,318225100383N/A
9/30/20221,437274103406N/A
6/30/20221,556323106430N/A
3/31/20221,597334130419N/A
12/31/20211,638346154409N/A
9/30/20211,515339124430N/A
6/30/20211,39233294451N/A
3/31/20211,18527532375N/A
12/31/2020978219-31299N/A
9/30/20201,00022113253N/A
6/30/20201,02222257207N/A
3/31/20201,15126257220N/A
12/31/20191,27930357233N/A
9/30/20191,23828232213N/A
6/30/20191,1972628194N/A
3/31/20191,18724653197N/A
12/31/20181,17623199201N/A
9/30/20181,100210119207N/A
6/30/20181,023189138214N/A
3/31/2018961178N/A204N/A
12/31/2017900167N/A194N/A
9/30/2017874159N/A166N/A
6/30/2017849151N/A138N/A
3/31/2017813144N/A114N/A
12/31/2016776136N/A90N/A
9/30/2016740126N/A63N/A
6/30/2016705115N/A37N/A
3/31/2016679110N/A53N/A
12/31/2015654105N/A69N/A
9/30/2015627101N/A75N/A
6/30/201560096N/A81N/A
3/31/201555986N/A58N/A
12/31/201451875N/A35N/A
9/30/201446667N/A43N/A
6/30/201441359N/A51N/A
3/31/201438057N/A58N/A
12/31/201334755N/A65N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1061's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 1061's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 1061's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1061's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 1061's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 1061's Return on Equity is forecast to be high in 3 years time


Discover growth companies